ADMA Biologics, Inc. (ADMA) vs Danaher Corporation (DHR)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ADMA | DHR | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Diagnostics & Research |
| Size band | MID | LARGE |
| Listing | Nasdaq GM | NYSE |
| Country | United States | United States |
| Theme | rare-disease | life-science-tools |
| Price and returns | ||
| Last close | $11.07 | $232.97 |
| Return · 1 week | −0.05% | +3.81% |
| Return · 1 month | +9.34% | +2.66% |
| Return · 3 months | +25.88% | +17.04% |
| Return · year to date | −38.12% | +1.33% |
| Return · 1 year | −29.07% | +5.78% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −45.91% | −4.05% |
| 52-week high | $20.46 | $242.80 |
| 52-week low | $7.21 | $160.93 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $2.48B | $163.77B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $28.67M | $834.36M |
| Employees | 640 | 58,000 |
| Valuation | ||
| Price to earnings · trailing | 15.26× | 39.18× |
| Price to earnings · forward | 11.32× | 23.64× |
| Price to sales | 4.67× | 6.15× |
| Price to book | 5.90× | 2.94× |
| Enterprise value to EBITDA | 10.97× | 22.06× |
| Enterprise value to revenue | 4.80× | 7.05× |
| PEG ratio | — | 1.29 |
| Earnings per share · trailing | 0.70 | 5.61 |
| Profitability | ||
| Gross margin | 64.71% | 58.51% |
| Operating margin | 42.16% | 19.78% |
| Profit margin | 32.98% | 15.89% |
| Return on equity | 41.90% | 7.61% |
| Return on assets | 21.78% | 3.95% |
| Growth | ||
| Revenue growth | +2.00% | +5.50% |
| Earnings growth | +14.30% | +59.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | 49.94 | 52.97 |
| Current ratio | 6.97 | 1.65 |
| Dividend yield | 0.00% | 0.74% |
| Payout ratio | 0.00% | 25.67% |
| Trend and volatility | ||
| RSI · 14 | 63.92 | 62.01 |
| ADX · 14 | 24.67 | 31.94 |
| 50-day average | $9.86 | $216.74 |
| 200-day average | $11.09 | $201.19 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.19% | 2.78% |
The full ADMA analysis
Everything this table leaves out for ADMA Biologics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ADMA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ADMA analysisThe full DHR analysis
Everything this table leaves out for Danaher Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the DHR argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full DHR analysis